Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary

Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business

Fagron, the global leader in pharmaceutical compounding, has reinforced its EMEA position with the acquisitions of a book of business from Amara (Poland) and Magilab (Hungary). These deals support Fagron’s strategy to diversify its presence in dynamic markets and highlight its disciplined M&A approach as a driver of sustainable growth. With these transactions, Fagron has executed 10 acquisitions this year, underscoring its disciplined serial acquirer track record.

The businesses combined are expected to contribute mid-teens (€m) in annual revenue, at an EBITDA margin above Fagron’s existing group margin. The combined purchase price amounts to approximately €26 million.

Separately, we have secured a new U.S. dollar credit facility with extended maturities to support our growth ambitions in North America, at attractive terms. We are very pleased to have achieved this milestone, which further strengthens our financial flexibility and long-term strategy.

The Company has also received a license for its Fagron Sterile Services (“FSS”) facility in Boston from the California State Board of Pharmacy. This allows us to ship compounding medication to that state, reinforcing our presence in one of the largest and most tightly regulated healthcare markets in the U.S.

Full press release